drugset / Trial / NCT03000660
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
This is a study to determine the safety, tolerability and maximum tolerated dose of Venetoclax (ABT-199) and dexamethasone in relapsed or refractory amyloid light chain (AL) amyloidosis patients.
Timeline
- Start
- 2017-01
- Primary completion
- 2019-10
- Completion
- 2019-10-10
Outcome
Outcome not reported
Stopped: “partial clinical hold per FDA”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venetoclax | Small molecule | 100 mg | Oral |
| Subject | Venetoclax | Small molecule | 200 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Subject | Venetoclax | Small molecule | 800 mg | Oral |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |